• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Percent of Office of In Vitro Diagnostics and Radiological Health (OIR) intra- and inter-Office eConsults completed on time during the month

Dictionary: CDRH uses the internal expert consultation process to acquire information and analysis on issues related to medical devices. Intra- and inter-office consultations are completed for a variety of work products requiring expertise within and across CDRH offices, including premarket device submissions, post-approval studies, and compliance and enforcement actions. Inter-office eConsults are used to facilitate the exchange of scientific information and staff expertise across CDRH, critical to making well-supported regulatory decisions. eConsult is the system CDRH uses to manage and monitor expert consult requests.

Information is current as of September 30, 2013

Fiscal Year - 2013

Skip graphic and jump to text data

TimeTargetPercent
Oct 20128594
Nov 20128592
Dec 20128592
Jan 20138596
Feb 20138592
Mar 20138591
Apr 20138596
May 20138594
Jun 20138595
Jul 20138595
Aug 20138592
Sep 20138587

FY 2013 Overall: 93%

Number of OIR intra- and inter-Office eConsults completed on time during the month

Fiscal Year - 2013
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2012N/A280
Nov 2012N/A273
Dec 2012N/A171
Jan 2013N/A277
Feb 2013N/A232
Mar 2013N/A236
Apr 2013N/A298
May 2013N/A226
Jun 2013N/A227
Jul 2013N/A336
Aug 2013N/A306
Sep 2013N/A261

FY 2013 Total: 3,138

Total number of OIR intra- and inter-Office eConsults completed during the month

Fiscal Year - 2013
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2012N/A297
Nov 2012N/A298
Dec 2012N/A186
Jan 2013N/A288
Feb 2013N/A251
Mar 2013N/A258
Apr 2013N/A311
May 2013N/A241
Jun 2013N/A239
Jul 2013N/A352
Aug 2013N/A333
Sep 2013N/A301

FY 2013 Total: 3,370

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.